Cencora (COR) Q3 2025 Earnings
How Did COR Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: +2.54%.
Did COR Beat Earnings? Q3 2025 Results
Yes. Cencora reported Q3 2025 earnings of $4.00 a share on Aug 6, 2025, beating the $3.84 consensus estimate by 4.2%. Revenue was $80.7B against a $80.1B estimate.
Cencora posted a standout fiscal third quarter, with revenue climbing 8.7% year-over-year to $80.66 billion and adjusted diluted EPS jumping 19.8% to $4.00, as the pharmaceutical distributor rode strong demand for GLP-1 class products and specialty pharmaceuticals across its U.S. Healthcare Solutions segment. That domestic engine, which generated $72.88 billion in revenue, saw segment operating income surge 29.1% to $901.79 million, with the January 2025 acquisition of Retina Consultants of America providing a meaningful lift to margins, pushing U.S. gross profit margin to 2.79% from 2.30% a year ago. Internationally, revenue grew 10.5% to $7.79 billion, though segment operating income fell 12.9% to $156.22 million on softness in specialty logistics and consulting. The solid domestic performance gave management confidence to raise full-year adjusted diluted EPS guidance to $15.85 to $16.00, with consolidated adjusted operating income growth now expected at 15% to 16%, even as some analysts flag the stock's elevated valuation as a reason for measured optimism.
- Overall pharmaceutical market growth driven by unit volume increases
- Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
- Growth in specialty products distributed to physician practices and health systems
- January 2025 acquisition of Retina Consultants of America (RCA) contributing to margin expansion
- LIFO credit of $52.1 million vs. LIFO expense of $6.8 million in prior year quarter
- Diluted shares outstanding decreased 2.4% due to share repurchases
“Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities.”
Cencora CEO, on the earnings call
What Was Cencora's Outlook in Q3 2025?
Cencora raised its fiscal year 2025 adjusted diluted EPS guidance to $15.85–$16.00 from $15.70–$15.95. Revenue growth is now expected at approximately 9% (narrowed from 8–10%). U.S. Healthcare Solutions segment revenue growth is expected at 9–10% (from 9–11%), with operating income growth of 20–21% (from 17.5–19.5%). International Healthcare Solutions segment revenue growth is expected at 6–7% (from 3–4%), but operating income is now expected to decline approximately 6% (from a decline of 1–4%). Adjusted consolidated operating income growth is expected at 15–16% (from 13.5–15.5%). Adjusted effective tax rate is expected at 20.5–21% (from approximately 21%).
COR YoY Financials
COR Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.